BrightView Heads Into Earnings With Options Traders on High Alert

Short interest tells a different, less alarming story. At roughly 4.8% of free float, the short position is meaningful but not crowded. It actually fell about 11% over the past month before nudging back up about 0.8% in the most recent session, suggesting shorts have been reducing rather than building. Borrow conditions are extremely loose — availability has expanded to more than 3,400% of outstanding short interest, with a cost to borrow near 0.44%. There is no lending pressure, no squeeze dynamic, and no sign that short sellers are scrambling for shares.

The analyst debate is genuine but split. The consensus sits at Buy, with a mean price target of $16.68 — implying roughly 27% upside from current levels. JP Morgan upgraded in May from Underweight to Neutral with a $14 target, a nod toward stabilisation rather than enthusiasm. Oppenheimer initiated at Outperform in June with a $17 target. But Goldman Sachs maintains a Sell with a $10.50 target, and Morgan Stanley holds Equal-Weight at $14. The forward EPS momentum factor ranks in just the 9th percentile over 90 days, and earnings surprise history is weak — both flags that the Bull case rests more on valuation and contract-cycle recovery than near-term estimate beats. EV/EBITDA near 6.9x and a price-to-book just above 1.0x keep the value argument alive, but the P/E has compressed sharply over the past month, down almost 1.8 turns, reflecting the price slide rather than earnings improvement.

The print is ultimately a test of whether BrightView's recurring commercial landscaping contracts are holding at margins that justify even the more cautious targets on the Street — or whether the month-long slide in the stock has been pricing in news that the numbers will confirm.

BV reported Q2 fiscal 2026 results on May 5th — and the print was a split verdict. Revenue topped estimates and full-year guidance moved higher, but EPS came in light. That combination explains the week: the stock…